JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Home・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

26.7 2.89

Buy Sell

Overview

Share price change

24h

Current

Min

26.5

Max

26.75

Key metrics
By Trading Economics
Income	-2.8M -57M
Sales	35K 730K
Profit margin	-7,753.425
Employees	186
EBITDA	-1.1M -63M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+84.06% upside

Dividends
By Dow Jones
Next Earnings	4 Nov 2025

Market Stats
By TradingEconomics
Market Cap	370M 1.8B
Previous open	23.81
Previous close	26.7

News Sentiment

By Acuity

100%

357 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Nov 2025, 22:13 UTC

Earnings

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 Nov 2025, 21:23 UTC

Earnings

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 Nov 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 Nov 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 Nov 2025, 21:00 UTC

Earnings

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 Nov 2025, 21:00 UTC

Earnings

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 Nov 2025, 21:00 UTC

Earnings

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 Nov 2025, 20:55 UTC

Earnings

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 Nov 2025, 20:55 UTC

Earnings

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 Nov 2025, 20:55 UTC

Earnings

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 Nov 2025, 20:46 UTC

Earnings

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 Nov 2025, 20:46 UTC

Earnings

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 Nov 2025, 20:45 UTC

Earnings

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 Nov 2025, 20:44 UTC

Earnings

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 Nov 2025, 20:43 UTC

Earnings

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 Nov 2025, 20:42 UTC

Earnings

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 Nov 2025, 20:41 UTC

Earnings

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 Nov 2025, 20:40 UTC

Earnings

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 Nov 2025, 20:39 UTC

Earnings

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 Nov 2025, 20:37 UTC

Earnings

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 Nov 2025, 20:37 UTC

Earnings

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 Nov 2025, 20:37 UTC

Earnings

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 Nov 2025, 20:36 UTC

Earnings

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 Nov 2025, 20:35 UTC

Earnings

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 Nov 2025, 20:35 UTC

Earnings

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 Nov 2025, 20:35 UTC

Earnings

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 Nov 2025, 20:34 UTC

Earnings

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 Nov 2025, 20:33 UTC

Earnings

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 Nov 2025, 14:27 UTC

Earnings

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 Nov 2025, 14:25 UTC

Earnings

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

84.06% upside

12 Months Forecast

Average 49.2 USD 84.06%

High 67 USD

Low 25 USD

Based on 12 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.